Immune‐related adverse events in the treatment of Hodgkin lymphoma with immune checkpoint inhibitors
British Journal of Haematology · 2026-05 · 208 (5) · 1608-1616
DOI: 10.1111/bjh.70402 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift British Journal of Haematology, online erschienen am 26.02.2026. Verfasst von Lisa Argnani und 9 weiteren Autor:innen. Beteiligte Einrichtung: Dipartimento di Scienze Mediche e Chirurgiche (DIMEC), Alma Mater Studiorum Università of Bologna, Bologna, Italy. Hauptthemen laut MEDLINE: Hodgkin Disease, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero della Salute.
Themen: Patientensicherheit
Abstract (Originalsprache)
Immune checkpoint inhibitors (ICIs) have shown to be effective in the treatment of Hodgkin lymphoma (HL). ICI treatment is associated with the occurrence of a series of immune‐related adverse events (irAEs). We conducted an ambispective observational study on 96 patients with relapsed/refractory HL treated with ICIs to determine the incidence of irAEs, their type, severity and their correlation with treatment outcomes. Fifty patients were treated with pembrolizumab (52.1%) and 46 patients were treated with nivolumab (47.9%). A total of 22 patients (22.9%) developed at least one irAE, resulting in a total of 27 irAEs. The results of our study did not show statistically significant differences between the two cohorts of patients, suggesting that the presence of these peculiar toxicities does not significantly impact outcomes and survivals in patients with HL treated with ICIs. However, the complexity of irAEs, their classification as such and the variability in response to immunotherapy require further studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dipartimento di Scienze Mediche e Chirurgiche (DIMEC), Alma Mater Studiorum Università of Bologna, Bologna, Italy.
- IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy.
- Division of Endocrinology and Diabetes Prevention and Care, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Förderung
- Ministero della Salute
Zitieren
APA
Argnani, L., Stefoni, V., Casadei, B., Pelusi, C., Preiato, V. L., Pagotto, U., Buganè, A., Pellegrini, C., Broccoli, A., & Zinzani, P. L. (2026). Immune‐related adverse events in the treatment of Hodgkin lymphoma with immune checkpoint inhibitors. British Journal of Haematology, 208(5), 1608-1616. https://doi.org/10.1111/bjh.70402
Vancouver
Argnani L, Stefoni V, Casadei B, Pelusi C, Preiato VL, Pagotto U, et al. Immune‐related adverse events in the treatment of Hodgkin lymphoma with immune checkpoint inhibitors. British Journal of Haematology. 2026;208(5):1608-1616. doi:10.1111/bjh.70402
BibTeX
@article{Argnani2026,
author = {Argnani, Lisa and Stefoni, Vittorio and Casadei, Beatrice and Pelusi, Carla and Preiato, Valentina Lo and Pagotto, Uberto and Buganè, Anna and Pellegrini, Cinzia and Broccoli, Alessandro and Zinzani, Pier Luigi},
title = {Immune‐related adverse events in the treatment of Hodgkin lymphoma with immune checkpoint inhibitors},
journal = {British Journal of Haematology},
year = {2026},
volume = {208},
number = {5},
pages = {1608--1616},
doi = {10.1111/bjh.70402}
}
EUVIMED